Chimerix Inc. (NASDAQ: CMRX) stock fell -1.89% on Friday to $1.04 against a previous-day closing price of $1.06. With 0.69 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.97 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0800 whereas the lowest price it dropped to was $1.0400. The 52-week range on CMRX shows that it touched its highest point at $2.39 and its lowest point at $0.92 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.12.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CMRX was down-trending over the past week, with a drop of -1.89%, but this was up by 8.33% over a month. Three-month performance dropped to -28.28% while six-month performance fell -22.39%. The stock lost -52.07% in the past year, while it has lost -44.09% so far this year. A look at the trailing 12-month EPS for CMRX yields 2.06 with Next year EPS estimates of -0.77. For the next quarter, that number is -0.23. This implies an EPS growth rate of 195.10% for this year and 14.40% for next year.
Float and Shares Shorts:
At present, 88.58 million CMRX shares are outstanding with a float of 79.56 million shares on hand for trading. On Aug 30, 2023, short shares totaled 1.78 million, which was 2.01% higher than short shares on Jul 30, 2023. In addition to Mr. Michael T. Andriole M.B.A. as the firm’s CEO, Pres & Director, Dr. Allen S. Melemed M.B.A., M.D. serves as its Chief Medical Officer.
Through their ownership of 61.89% of CMRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 10.00% of CMRX, in contrast to 35.15% held by mutual funds. Shares owned by individuals account for 19.51%. As the largest shareholder in CMRX with 4.94% of the stake, Monaco Asset Management SAM holds 4,377,674 shares worth 4,377,674. A second-largest stockholder of CMRX, The Vanguard Group, Inc., holds 4,163,131 shares, controlling over 4.70% of the firm’s shares. Armistice Capital LLC is the third largest shareholder in CMRX, holding 3,176,000 shares or 3.59% stake. With a 3.28% stake in CMRX, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,904,360 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.48% of CMRX stock, is the second-largest Mutual Fund holder. It holds 1,306,306 shares valued at 1.49 million. Pictet Asset holds 0.91% of the stake in CMRX, owning 805,138 shares worth 0.92 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, CMRX reported revenue of $440.00k and operating income of -$23.45M. The EBITDA in the recently reported quarter was -$23.42M and diluted EPS was -$0.27.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CMRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CMRX analysts setting a high price target of $11.00 and a low target of $5.00, the average target price over the next 12 months is $7.00. Based on these targets, CMRX could surge 957.69% to reach the target high and rise by 380.77% to reach the target low. Reaching the average price target will result in a growth of 573.08% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded CMRX stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 25,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 375,215 while 7,630 shares were sold.